"Designing Growth Strategies is in our DNA"
Neuroendocrine tumours basically occur in the neuroendocrine cells which possess properties of both, nerve cells and hormone-producing cells. Depending upon the tumour location, neuroendocrine tumours are classified as gastrointestinal neuroendocrine tumours, lung neuroendocrine tumours, pancreatic neuroendocrine tumours, and Zollinger-Ellison syndrome (small intestine). Discomfort or pain in the abdomen or rectum, diarrhoea, bleeding from the rectum or blood in the stool, and blockage in the intestine (bowel obstruction) are some of the commonly observed symptoms of gastrointestinal neuroendocrine tumours. According to National Institutes of Health, neuroendocrine tumours account for an estimated 0.5% all newly diagnosed cases of malignancies.
Certain therapies such as somatostatin analogues, targeted therapy, radiofrequency ablation, and peptide receptor radionuclide therapy (PRRT) are commonly recommended in order to treat neuroendocrine tumours.
Pharmaceutical companies are prominently focusing on studying and developing new treatment options for the neuroendocrine tumours. For instance; Surufatinib, which is being studied by Hutchison Medipharma Limited, is currently in phase-3 clinical trials to check its efficacy and tolerability for the treatment of advanced extrapancreatic neuroendocrine tumors.
To know how our report can help streamline your business, Speak to Analyst
At present around 90% of the pipeline candidates for neuroendocrine tumours are in the phase-1 and phase-2 stage. Majority of the studies have been sponsored by pharmaceutical companies.
The report on ‘Neuroendocrine Tumours – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Neuroendocrine Tumours. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Neuroendocrine Tumours.
The report on ‘Neuroendocrine Tumours – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players